76 related articles for article (PubMed ID: 23548965)
1. Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients.
Kaplan MA; Inal A; Kucukoner M; Urakci Z; Ekici F; Firat U; Zincircioglu SB; Isikdogan A
Onkologie; 2013; 36(4):176-81. PubMed ID: 23548965
[TBL] [Abstract][Full Text] [Related]
2. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
Duchnowska R; Dziadziuszko R; Czartoryska-Arłukowicz B; Radecka B; Szostakiewicz B; Sosińska-Mielcarek K; Karpińska A; Starosławska E; Kubiatowski T; Szczylik C
Breast Cancer Res Treat; 2009 Sep; 117(2):297-303. PubMed ID: 19130219
[TBL] [Abstract][Full Text] [Related]
5. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B; Benekli M; Oksuzoglu B; Koral L; Ulas A; Dane F; Turker I; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Isıkdogan A; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
Onkologie; 2012; 35(12):740-5. PubMed ID: 23207619
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
Niwińska A; Murawska M; Pogoda K
Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
9. Limited overall survival in patients with brain metastases from triple negative breast cancer.
Morris PG; Murphy CG; Mallam D; Accordino M; Patil S; Howard J; Omuro A; Beal K; Seidman AD; Hudis CA; Fornier MN
Breast J; 2012; 18(4):345-50. PubMed ID: 22607041
[TBL] [Abstract][Full Text] [Related]
10. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
12. Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry.
Laakmann E; Witzel I; Scriba V; Grzyska U; Zu Eulenburg C; Burchardi N; Hesse T; Würschmidt F; Fehm T; Möbus V; von Minckwitz G; Loibl S; Park-Simon TW; Mueller V
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669228
[TBL] [Abstract][Full Text] [Related]
13. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
14. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer.
Xu Z; Marko NF; Chao ST; Angelov L; Vogelbaum MA; Suh JH; Barnett GH; Weil RJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e739-47. PubMed ID: 22024205
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
18. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
19. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
[TBL] [Abstract][Full Text] [Related]
20. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer.
Baek JM; Jin Q; Ensor J; Boulbes DR; Esteva FJ
Breast Cancer Res Treat; 2011 Dec; 130(3):1029-36. PubMed ID: 21830016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
